Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Astrego Diagnostics AB in conjunction with capital procurement
Mandate

Vinge advises Astrego Diagnostics AB in conjunction with capital procurement

January 29, 2020 M&A

Vinge has advised Astrego Diagnostics AB in connection with the investment in the company by the Japanese company Sysmex Corporation, which has acquired approximately 25% of the shares in the company.

Astrego develops a ground‑breaking technology for characterization of antibiotic‑sensitivity. The first product gives doctors a patient specific diagnostic tool for urinary infections.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg and Viktoria Owetz Leyva.

Related

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

 Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

 Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026